Other Clinical Trial - 12-Month Once-a-week HIIT Improves Body Adiposity &

Status Active, not recruiting

Clinical Trial Summary

Obesity and non-alcoholic fatty liver disease (NAFLD) are two related growing epidemics that are becoming pressing public health concerns. High-intensity interval training (HIIT) is a promising cost-effective and time-efficient exercise modality for managing obesity and NAFLD. However, patients with obesity and NAFLD are generally inactive and unfit, and might feel intimidated by the frequency of the prescribed HIIT (conventionally three times weekly). Previous HIIT studies, mostly over 2-4 month periods, showed that the participants could accomplish this exercise frequency under a controlled laboratory environment, but the long-term adherence and sustainability, especially in a field setting, remains uncertain. The situation is more unclear if we also consider those individuals who refused to participate possibly because of their overwhelming perceptions or low self-efficacy toward HIIT. Thus, logically, HIIT at a lower frequency would be practical and more suitable for patients with obesity and NAFLD, but the minimum exercise frequency required to improve health, especially in the long-term, is unknown. This proposed study aims to examine the effectiveness of long-term low-frequency HIIT for improving body adiposity and liver fat in centrally obese adults. The premise of this proposal is supported by recent findings that HIIT performed once a week could improve cardiorespiratory fitness, blood pressure, cardiac morphology, metabolic capacity, muscle power, and lean mass. This study will provide evidence for the benefits of long-term low-frequency HIIT with a follow-up period to assess its effectiveness, safety, adherence, and sustainability. We expect this intervention will enhance the practical suitability of HIIT in inactive obese adults and will provide evidence for low-frequency HIIT as a new exercise option in the management of obesity and NAFLD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03912272
Study type	Interventional
Source	The University of Hong Kong
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 1, 2019
Completion date	January 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05480696` - Soluble Fibre Supplementation in NAFLD	Phase 1
Active, not recruiting	`NCT02500147` - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)	Phase 4
Completed	`NCT04671186` - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan	N/A
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Recruiting	`NCT05462353` - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH	Phase 2
Completed	`NCT05006885` - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)	Phase 1
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Recruiting	`NCT04365855` - The Olmsted NAFLD Epidemiology Study (TONES)	N/A
Recruiting	`NCT05618626` - Prevention of NAFLD and CVD Through Lifestyle Intervention	N/A
Completed	`NCT03256526` - 6-week Safety and PD Study in Adults With NAFLD	Phase 2
Enrolling by invitation	`NCT06152991` - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy	Phase 3
Completed	`NCT03681457` - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects	Phase 1
Completed	`NCT06244550` - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Completed	`NCT03060694` - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed	`NCT02526732` - Hepatic Inflammation and Physical Performance in Patients With NASH	N/A
Recruiting	`NCT01988441` - The Influence of Autophagy on Fatty Liver
Recruiting	`NCT01680003` - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease	Phase 2
Completed	`NCT01712711` - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease	Phase 2
Recruiting	`NCT00941642` - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms